UDK: 616.65-085.31:616.12
M. E. Statsenko, S. V. Turkina, I. A. Tyschenko, S. A. Kostromeev
Волгоградский государственный медицинский университет, кафедра внутренних болезней педиатрического и стоматологического факультетов, кафедра урологии, нефрологии и трансплантологии ФУВ
The risk of erectile dysfunction (ED) in patients with arterial hypertension, coronary heart disease increases when patients use drugs to treat these cardiac pathologies. In addition, ED is common in elderly men undergoing transurethral endoscopic interventions. In this connection, it is very important to develop an integrative (multidisciplinary) approach to evaluating the efficacy and safety of treatment of ED in patients with cardiovascular diseases, as well as those who had transurethral resection of the prostate gland for benign prostatic hyperplasia. The study to assess the efficacy and safety of sildenafil in patients with cardiovascular diseases demonstrated that sildenafil at a dose of 50 mg or 100 mg an hour before anticipated sexual activity is an effective means both in cardiovascular patients and those who underwent transurethral resection of the prostate.
erectile dysfunction, cardiovascular diseases, transurethral endoscopic intervention, sildenafil